iStock_37438014_XXXLARGE-outlined_LM.png pink_scrubs.png hp-people-3.png man-in-sweater_90824869_v1MAG.png Dr-Glasses.png iStock_86712797_XXXLARGE-outline_LM.png blue_shirt_masthead_man_v1_MAG.png NKT-hp-people-Michelle_v1_LM.png iStock_68713947_XXLARGE-outiline_LM.png NKT-hp-people-Phi_v1_LM.png NKT-hp-people-Mekhala_v1_LM.png hp-people-3.png iStock_87627749_XXXLARGE-outline_LM.png

Events

JUN 03

Nektar Analyst & Investor Event at 2017 ASCO Annual Meeting
Chicago, IL
4:00 p.m. PDT / 6 p.m. CDT

Webcast Link

MAR 20

SUMMIT-07 Phase 3 Study Results
San Francisco, CA
8:45 a.m. EDT / 5:45 a.m. PDT

Webcast Link

Leadership Spotlight

Dr. Jonathan Zalevsky, VP, Biology discusses NKTR-214

Watch

OUR PIPELINE

We are focused on using new chemistry approaches to make better medicines to treat cancer, chronic pain and auto-immune disease.

  • 9

    9 million patients benefit from our medicines

    9
    9
    9
  • 12

    12 approved products around the world

    12
    12
    12
  • 10

    10 new medicines in development pipeline

    10
    10
    10


Cutting-edge facilities




Dynamic teams




Impactful work


OUR Culture

We are supported by a dynamic team, rich in scientific, business and medical expertise, across three locations.

Read more